- Healthcare Professionals
- Research
- Clinical trials
- 2693-cl-1303
2025-07-01T00:00:00.000+01:00
Ongoing
2693-CL-1303
2693-CL-1303
Breast Cancer
A randomized, placebo-controlled, double-blind, phase 3 clinical study to investigate the efficacy and safety of fezolinetant for the treatment of moderate to severe vasomotor symptoms (hot flashes) in women with stage 0 to 3 hormone receptor-positive breast cancer who are receiving adjuvant endocrine therapy.
A randomized, placebo-controlled, double-blind, phase 3 clinical study to investigate the efficacy and safety of fezolinetant for the treatment of moderate to severe vasomotor symptoms (hot flashes) in women with stage 0 to 3 hormone receptor-positive breast cancer who are receiving adjuvant endocrine therapy.
Trial overview
Disease
Breast cancer
Topic
Diagnostics
Sponsor
Astellas Pharma
Description
A randomized, placebo-controlled, double-blind, phase 3 clinical study to investigate the efficacy and safety of fezolinetant for the treatment of moderate to severe vasomotor symptoms (hot flashes) in women with stage 0 to 3 hormone receptor-positive breast cancer who are receiving adjuvant endocrine therapy.
Study details
For detailed information on this trial, please click here
Trial status
Opening July 2025
Location
Oxford
:::
Principal Investigator
Dr. Rene Roux